Published in

National Academy of Sciences, Proceedings of the National Academy of Sciences, 25(114), 2017

DOI: 10.1073/pnas.1615730114

Links

Tools

Export citation

Search in Google Scholar

Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells

Journal article published in 2017 by Davide Genini, Lara Brambilla, Erik Laurini ORCID, Jessica Merulla, Gianluca Civenni, Shusil Pandit, Rocco D'Antuono ORCID, Laurent Perez ORCID, David E. Levy, Sabrina Pricl ORCID, Giuseppina M. Carbone, Carlo V. Catapano
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Significance The transcription factor STAT3 is involved in multiple oncogenic signaling pathways and is an attractive therapeutic target. This study shows that a potent inhibitor of STAT3 interferes with mitochondrial activity and protein homeostasis, leading to a synthetic lethality effect in glucose-depleted cancer cells. These findings provide a rationale for novel strategies based on the use of STAT3 inhibitors for cancer treatment.